Celldex Therapeutics (FRA:TCE2) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TCE2 Celldex Therapeutics Inc FRA:TCE2
61 GF Score
Price €30.50
GF Value €5.92
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:TCE2
61GF Score
Celldex Therapeutics Inc FRA:TCE2
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celldex Therapeutics (FRA:TCE2) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of €30.50 is trading 415.2% above its estimated GF Value™ of €5.92. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:TCE2:

  • Dividends Received:
  • GF Value™: €5.92 vs. price of €30.50 (415.2% above fair value)
  • GF Score™: 61/100 with 8 warning signs

No single metric tells the full story. See the FRA:TCE2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges CLDX:USA
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
61GF Score

Get the complete analysis for FRA:TCE2

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.50
Price
€5.92
GF Value